JP7235270B2 - 血糖値上昇抑制剤及び同血糖値上昇抑制剤の製造方法 - Google Patents
血糖値上昇抑制剤及び同血糖値上昇抑制剤の製造方法 Download PDFInfo
- Publication number
- JP7235270B2 JP7235270B2 JP2018021612A JP2018021612A JP7235270B2 JP 7235270 B2 JP7235270 B2 JP 7235270B2 JP 2018021612 A JP2018021612 A JP 2018021612A JP 2018021612 A JP2018021612 A JP 2018021612A JP 7235270 B2 JP7235270 B2 JP 7235270B2
- Authority
- JP
- Japan
- Prior art keywords
- blood sugar
- butyric acid
- blood
- inhibitor
- acid bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Description
血糖値上昇抑制剤の調製は次の通り行った。まず、100gのコーンスターチと、2.8gのアミノ酸液と、20gの炭酸カルシウムとを計量し、10Lのコルベンに計量した各原料を投入して攪拌しつつ温水で5Lにアップして培養液を得た。培養液はその後蒸気滅菌に供し、冷却した。
次に、糖尿病モデルラットを用い、本実施形態に係る血糖値上昇抑制剤の効果と有用性について確認を行った。
次に、本実施形態に係る血糖値上昇抑制剤A1がヒトの血糖値に対しどのような影響を及ぼすかについて検討を行った。被験者は79歳の男性であり、2016年以前より血糖等(HbA1c)に関する定期検査を実施している。今回、本実施形態に係る血糖値上昇抑制剤の血糖に対する知見を得るため、自主的に本製剤を60ml/日量を摂取する事で血糖指標であるHbA1cの推移を調査した。その結果を図5に示す。
Claims (1)
- 酪酸菌C.butyricum(ただし、ボツリヌス毒素を産生する菌株を除く。)がGAM培地にて予め培養された1容量部のスターターを、2w/v%のコーンスターチと0.056w/v%のアミノ酸液と0.4w/v%の炭酸カルシウムを含む5容量部の滅菌済培養液に接種し、25~40℃にて18~48時間に亘り嫌気条件下でpHが5.2~4.5に至るまで培養して得られた発酵液からなり、
前記発酵液は、前記酪酸菌が実質的に除去された上清画分であり、
高血糖状態の動物に対し、同動物の体重1kgあたり0.3~1.0mlの量の前記発酵液を毎日継続的に飲用させて血糖値の正常化を行うための血糖値上昇抑制剤の製造方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018021612A JP7235270B2 (ja) | 2018-02-09 | 2018-02-09 | 血糖値上昇抑制剤及び同血糖値上昇抑制剤の製造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018021612A JP7235270B2 (ja) | 2018-02-09 | 2018-02-09 | 血糖値上昇抑制剤及び同血糖値上昇抑制剤の製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019137631A JP2019137631A (ja) | 2019-08-22 |
JP7235270B2 true JP7235270B2 (ja) | 2023-03-08 |
Family
ID=67693188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018021612A Active JP7235270B2 (ja) | 2018-02-09 | 2018-02-09 | 血糖値上昇抑制剤及び同血糖値上昇抑制剤の製造方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7235270B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110638841B (zh) * | 2019-09-25 | 2024-02-20 | 山东艾克韦生物技术有限公司 | 一种益生菌和益生元复合制剂、其制备方法及其用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100104602A1 (en) | 2007-06-25 | 2010-04-29 | Pasricha Pankaj J | Neurotoxin therapy for postprandial hyperglycemia |
JP2010248185A (ja) | 2009-03-26 | 2010-11-04 | Biofuerumin Seiyaku Kk | 血糖降下作用増強剤 |
CN104432001A (zh) | 2013-09-18 | 2015-03-25 | 深圳华大基因科技有限公司 | 可食用组合物及其用途 |
CN105769928A (zh) | 2016-03-25 | 2016-07-20 | 江南大学 | 丁酸梭状芽孢杆菌在防治或辅助治疗高血糖制剂中的应用 |
CN106176833A (zh) | 2016-08-31 | 2016-12-07 | 佛山市艳晖生物科技有限公司 | 一种防治糖尿病并控制体重的复合益生菌液及其制备方法 |
WO2017159643A1 (ja) | 2016-03-14 | 2017-09-21 | 物産フードサイエンス株式会社 | 腸内酪酸増加剤および酪酸産生菌増殖剤 |
-
2018
- 2018-02-09 JP JP2018021612A patent/JP7235270B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100104602A1 (en) | 2007-06-25 | 2010-04-29 | Pasricha Pankaj J | Neurotoxin therapy for postprandial hyperglycemia |
JP2010248185A (ja) | 2009-03-26 | 2010-11-04 | Biofuerumin Seiyaku Kk | 血糖降下作用増強剤 |
CN104432001A (zh) | 2013-09-18 | 2015-03-25 | 深圳华大基因科技有限公司 | 可食用组合物及其用途 |
WO2017159643A1 (ja) | 2016-03-14 | 2017-09-21 | 物産フードサイエンス株式会社 | 腸内酪酸増加剤および酪酸産生菌増殖剤 |
CN105769928A (zh) | 2016-03-25 | 2016-07-20 | 江南大学 | 丁酸梭状芽孢杆菌在防治或辅助治疗高血糖制剂中的应用 |
CN106176833A (zh) | 2016-08-31 | 2016-12-07 | 佛山市艳晖生物科技有限公司 | 一种防治糖尿病并控制体重的复合益生菌液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2019137631A (ja) | 2019-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Salamone et al. | Moro orange juice prevents fatty liver in mice | |
Inoue et al. | Blood-pressure-lowering effect of a novel fermented milk containing γ-aminobutyric acid (GABA) in mild hypertensives | |
EP1429602B1 (en) | Methods for treating disorders using plant extracts | |
JP6684966B2 (ja) | 新規なラクトバチルス・サケイ及びそれを含む組成物 | |
Shi et al. | The effects of supplementation with blueberry, cyanidin-3-O-β-glucoside, yoghurt and its peptides on obesity and related comorbidities in a diet-induced obese mouse model | |
Kim et al. | Efficacy and safety of fermented garlic extract on hepatic function in adults with elevated serum gamma-glutamyl transpeptidase levels: A double-blind, randomized, placebo-controlled trial | |
CN113308421B (zh) | 一种植物乳杆菌bufx及其在代谢综合征中的应用 | |
US11730783B2 (en) | Active substance of Morchella, its use and a composition thereof for improving the reproductive function | |
JP5592640B2 (ja) | 乳酸菌発酵ローヤルゼリーを含有する抗ストレス剤、その製造方法、視床下部−下垂体−副腎皮質系の活動抑制剤、及び交感神経−副腎髄質系の活動抑制剤 | |
JP2019011353A (ja) | 茶発酵物 | |
CN109893544A (zh) | 用于预防和治疗代谢类疾病的土壤制剂及其制备方法与应用 | |
Rocchetti et al. | Oleuropein from olive leaf extracts and extra-virgin olive oil provides distinctive phenolic profiles and modulation of microbiota in the large intestine | |
JP7235270B2 (ja) | 血糖値上昇抑制剤及び同血糖値上昇抑制剤の製造方法 | |
CN104017746B (zh) | 乳杆菌、其组合物与用于制备治疗红斑性狼疮引起的心脏与肝脏病变的应用 | |
Zulkawi et al. | Antihyperglycemic and anti-inflammatory effects of fermented food paste in high-fat diet and streptozotocin-challenged mice | |
Pyo et al. | Hypoglycemic and hypolipogenic action of acetic acid and Monascus-fermented grain vinegar: a comparative study | |
CN100496263C (zh) | 降血糖的酸奶 | |
CN110151848A (zh) | 橘皮发酵物及其制备方法与应用 | |
JP2017507148A (ja) | 活性化ダイズさや繊維 | |
CN104415023A (zh) | 预防或/和治疗胰岛素抵抗及相关病症的组合物 | |
Liu et al. | Lotus seed resistant starch and sodium lactate regulate small intestinal microflora and metabolite to reduce blood lipid | |
Amin et al. | Effect of cocoa powder extract on plasma glucose levels in hyperglycaemic rats | |
Sasmita et al. | Potential use of fermented dangke cheese to improve glycemic control in rats fed with a high-fat glucose diet and propylthiouracil | |
JP2019210269A (ja) | 糖尿疾患の治療用組成物 | |
Huang et al. | Preparation and hypoglycemic effects of chromium-and zinc-rich Acetobacter aceti |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201023 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220614 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221013 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230117 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230216 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7235270 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |